Bio-Thera Solutions and SteinCares announced the signing of a new agreement to commercialize a proposed biosimilar of dupilumab across Latin America. This is the fourth product that the two companies agree to collaborate and strengthens their shared commitment to improving access to high-quality, cost-effective therapies in the region. Under the agreement, Bio-Thera will be responsible for product development and supply, while SteinCares will lead the registration and commercialization process throughout Latin America.
"Expanding access to advanced therapies while making healthcare more affordable is central to our mission," said Mitchell Waserstein, Chief Executive Officer at SteinCares. "Through this collaboration, we are reinforcing our position as one of the region's most robust biosimilar platforms in Latin America, offering a broad portfolio and pipeline tailored to the needs of patients and health systems across the region."
Dupilumab is one of the top five medicines globally in terms of annual sales value, so this biosimilar is a significant milestone in SteinCares' expansion. The new partnership will potentially support the treatment of chronic inflammatory conditions in both adults and children.
"This collaboration underscores our continued trust in SteinCares as a regional partner with strong regulatory, commercial, and medical capabilities," said Dr. Shengfeng Li, CEO of Bio-Thera Solutions. "By leveraging well-established commercial network of SteinCares, we aim to accelerate the delivery of safe, high-quality and affordable therapies to patients across Latin America."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!